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Lipoprotein glomerulopathy (LPG) is a rare inherited disease caused by mutations in
the APOE gene, encoding apolipoprotein E (apoE). Atypical hemolytic uremic syndrome
(aHUS) is a thrombotic microangiopathy (TMA) characterized by overactivation of the
alternative complement pathway. Here we report the case of a 21-year-old man with LPG
who developed aHUS. A functional complement assay demonstrated an overactivation
of the complement system. Complementary genetic analysis revealed a homozygous
aHUS risk allele for complement factor-H related 1 (CFHR1), CFHR1∗B. To the best of
our knowledge, this is the first report of an aHUS in a patient with LPG.
Keywords: case report, lipoprotein glomerulopathy, thrombotic microangiopathy, atypical hemolytic uremic
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INTRODUCTION
Lipoprotein glomerulopathy (LPG) is a rare inherited renal disease caused by mutations in the
APOE gene, encoding apolipoprotein E (apoE) (1). Approximately 200 LPG cases have been
reported worldwide, the majority in Asian populations (2). LPG is an autosomal dominant disorder
with incomplete penetrance (1, 3). Gene analysis discovered various mutations of APOE. Most of
them are missense variants close to the LDL receptor binding site. However, mutants far from
the binding site and mutants involving deletion of several amino acids are also reported (4).
The clinical manifestation and histological findings seem to be common with different APOE
variants (1). A kidney biopsy is essential for LPG diagnosis (3). Pathognomonic histologic features
include glomerular capillary lipid thrombi without significant infiltration by foamy macrophages
(5, 6). Clinically the disease manifests with proteinuria or nephrotic syndrome with or without an
abnormal lipid profile and may gradually progress to chronic renal failure (1).
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA)
characterized by overactivation of the alternative complement pathway (7). Complement factor
H (CFH) is the primary inhibitor of this pathway (Figure 2A). The complement factor H-related
(CFHR) gene family encodes a group of plasma proteins genetically and structurally related to CFH.
The risk allotype CFHR1∗B (Figure 2B), resulting from a gene conversion event between CFH and
CFHR1, is strongly associated with aHUS. In this report, we present a case of LPG with aHUS.
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CASE DESCRIPTION
A 21-year-old swiss-indonesian man was referred to our
nephrology clinic in June 2019. He had end-stage renal disease
with a creatine value of 907 µmol/l (Table 1). Previously,
at the age of 14 years, an asymptomatic, increased blood
pressure of 158/102mmHgwas discovered during a school-based
examination, and he was investigated at the children’s hospital
of Lucerne, Switzerland. His medical history revealed swollen
eyelids in the morning for the last 3 years. Clinical examination
was regular except for bilateral ankle edema. Further workup
identified a nephrotic syndrome with a protein to creatine ratio
of 586 mg/mmol, a serum albumin concentration of 27 g/L, total
cholesterol of 9.5 mmol/l (Table 1), and microhematuria with
30% dysmorphic erythrocytes. Screening for hepatitis B and C
was negative, and autoantibodies (antinuclear antibodies, anti
dsDNA antibodies, antineutrophil cytoplasmic antibodies, and
antiglomerular basement membrane antibodies) were negative.
Echocardiography showed mild left ventricular hypertrophy.
The renal biopsy established the diagnosis of LPG. It showed
glomerular capillary dilatations with lipoprotein thrombi with
lamella formation (Figure 1A). No fibrin thrombi, fragmented
erythrocytes or fibrinoid necrosis suggestive of aHUS was
seen. Chronic changes in the form of secondary focal





8-days after 12-days after
Blood
Hematology
Hemoglobin (140–180 g/L) 127 g/L 84 g/L 77 g/L 63 g/L
Fragmentocytes NA neg. neg. pos.
Platelet count (150–350 × 109/L) 374 × 109/L 114 × 109/L 43 × 109/L 51 × 109/L
Chemistry
Potassium (3.5–5.1 mmol/L) 3.69 mmol/L 5.49 mmol/L 4.92 mmol/L 4.83 mmol/L
Phosphate (0.87–1.45 mmol/L) 1.42 mmol/L 2.24 mmol/L 1.97 mmol/L 2.41 mmol/L
Creatinine (62–106 µmol/L) 71 µmol/L 907 µmol/L 1,006 µmol/L 985 µmol/L
Urea (<8.3 mmol/L) 5.6 mmol/L 31.7 mmol/L 29.6 mmol/L 32.3 mmol/L
LDH (135–225 U/L) NA 151 U/L 241 U/L 227 U/L
Haptoglobin (0.3–2.0 g/L) NA 0.47 g/L <0.1 g/L NA
Total bilirubin (<21.0 µmol/L) 4 µmol/L 5.0 µmol/L 7.1 µmol/L NA
Albumin 27 g/L NA 43 g/L 42 g/L
Total cholesterin (<5 mmol/L) 9.52 mmol/L NA 2.9 mmol/L NA
Cholesterin-HDL (>1 mmol/L) 1.47 mmol/L NA 1.3 mmol/L NA
Cholesterin-LDL 7.57 mmol/L NA 1.4 mmol/L NA
Triglyceride (<2 mmol/L) 1.63 mmol/L NA 1.6 mmol/L NA
Complement and ADAMTS-13
C3 (0.9–1.8 g/L) 1.05 g/L 0.81 g/L 0.74 g/L NA
C4 (0.1–0.4 g/L) 0.19 g/L 0.20 g/l 0.21 g/L NA
ADAMTS-13 activity NA NA NA 100%
Urine
Prot/Creat ratio (<11.3 mg/mmol) 586 mg/mmol 230 mg/mmol NA NA
*NA, non-available.
segmental scleroses and mild interstitial fibrosis with tubular
atrophy were already present. By immunohistochemistry,
mild to moderate unspecific depositions of IgM and C5b-
9 within the glomeruli were detected. IgA, IgG, and C3c
were negative within the glomeruli. Transmission electron
microscopy showed the characteristic concentrically layered
and vacuolated lipoprotein thrombi (Figure 1B). Analysis of
APOE revealed E3/E3 genotype. Sequencing of the APOE gene
detected a heterozygous 9-bp deletion in exon 4 (NM_000041.3:
c.480_488del (p.Leu162_Lys164del, traditional nomencalture:
142_144del)), resulting in a 3-amino acid deletion in a region
involved in receptor binding of the apo E molecule and
previously associated with LPG (10, 11). In the literature,
this mutation is often named APOE Tokyo/Maebashi (1). A
grandfather of the patient in Indonesia received a kidney
transplant at the age of about 60 years. Otherwise, the family
history brought to light no renal disease in either of the
patient’s parents. The patient has no siblings. Therapy was
started with an ACE-inhibitor (enalapril 10 mg/d) and a lipid-
lowering agent (atorvastatin 20 mg/d). As the patient emigrated
to Indonesia soon after the diagnosis, medical follow-up
was lost.
In June 2019, after his return to Switzerland, he complained
about fatigue, epigastric pain, and a dizzy sensation. Blood
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FIGURE 1 | Glomerulus with intraglomerular lipoprotein thrombi. (A) Glomerulus with dilated glomerular capillaries containing characteristic acellular, lamellated,
intracapillary lipoprotein thrombi. PAS staining. (B) Dilated peripheral glomerular capillary containing a lipoprotein thrombus with its characteristic electron microscopic
appearance. While the endothelial cells on the left-hand side are visible and slightly enlarged, they are not detectable in the upper right side. Transmission electron
microscopy.
Frontiers in Medicine | www.frontiersin.org 3 June 2021 | Volume 8 | Article 679048
Kollbrunner et al. Lipoprotein Glomerulopathy and aHUS
FIGURE 2 | Complement activation cascade. Factor H and factor H related (FHR) 1 allotypes. (A) The complement system has three pathways (8). The classical
pathway (CP) is triggered by antibody-antigen complexes interacting with C1q. The lectin pathway (LC) is triggered when lectins, e.g., mannose binding lectin (MBL),
bind carbohydrates on surfaces. Both pathways lead to cleavage of C4 and C2, enabling the assembly of the C3 convertase C4b2a. The alternative pathway (AP) is
constitutively active at low levels due to the spontaneous transformation of C3 to C3(H2O). This product is functionally C3b-like and allows the formation of the fluid
phase C3 convertase C3(H2O)Bb. The latter cleaves C3 and enables the formation of the cell surface alternative pathway C3 convertase C3bBb. Factor H, the master
regulator of the AP, interferes with this pathway at multiple levels (red). Assembly of the C5 convertases C4b2a3b and C3bBb3b initiates the last phase of the
complement cascade, which is identical for all three pathways. (B) CFHR1 encoding FHR1 is a member of the factor H gene family. FHR1 comprises five short
consensus repeats (SCRs) with different degrees of identity with homologous domains of factor H. The allotype CFHR1*B is associated with an increased risk for
aHUS if present in homozygosity. FHR1*B harbors the amino acids Tyr at position 157, Val at 159, and Gln at 173 in SCR3, which are identical to those in SCR 18 of
factor H (9). (C) Factor H is composed of 20 SCR domains arranged like beads on a string. On cell surfaces, factor H induces dissociation of surface-bound C3bBb
and inactivation of C3b. The high sequence similarity of FHR1*B to factor H may lead to a competition between factor H and FHR1*B, a consecutive decrease of the
functional activity of factor H and thus predisposing to aHUS (9).
pressure was 171/106 mmHg. No edema was noticed. In contrast
to the findings 7 years earlier, the lipid profile was normal.
The laboratory results showed progressive thrombocytopenia
and coombs-negative hemolytic anemia with fragmentocytes
(Table 1), and the diagnosis of thrombotic microangiopathy
(TMA) was made. At this time, C3 levels were reduced.
ADAMTS13 activity was 100% (Table 1). We started dialysis in
July 2019, shortly after his first emergency consultation in our
clinic. Due to a paracentral scotoma (left > right) fundoscopic
exam was performed, which showed hypertensive retinopathy.
A magnetic resonance imaging (MRI) of the brain was normal.
A detailed, further analysis of the complement system revealed
a functional complement defect (Table 2) and the presence of a
homozygous aHUS risk allele for CFHR1, CFHR1∗B (Table 3).
Factor H antibodies were negative. Currently, the patient is listed
for renal transplantation. We plan to treat the patient with
the C5 inhibitor eculizumab during the first 3–6 months after
transplantation. Close monitoring of the complement activity,
i.e., CH50 test and C3 levels, will be required. Also, protocol
biopsies will help us to detected aHUS and LPG recurrence at
an early stage. Depending on posttransplant lipid levels and the
results of protocol biopsies, we plan to treat the patient with
TABLE 2 | C5b-9 complement deposition on human microvascular endothelial
cells (HMEC-1).




The table shows the results of an ex vivo functional complement assay. In short,
confluent human microvascular endothelial cells (HMEC-1) were maintained unstimulated
or activated with 10 µmol/l ADP for 10min and then incubated with the patient’s
serum or control serum for 2 of 4 h, respectively. HMEC-1 were fixed and stained with
rabbit anti-human C5b-9 antibody followed by a fluorescein isothiocyanate–conjugated
secondary antibody. Fluorescent staining on the cell surface was acquired through
confocal microscopy. The stained area was evaluated using the Image J software. Results
are expressed as a percent of staining in relation to the control serum (12).
fibrates as their use can induce clinical remission in some patients
with LPG (3).
DISCUSSION
We present a case of a young, swiss-indonesian man with
LPG. The initial manifestation was hypertension and nephrotic
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TABLE 3 | Complement system: sequencing analysis by Next-Generation
Sequencing (NGS).
Genes Result
Complement factor H (CFH)
including the non-coding portion upstream
of the gene containing the variant
rs3753394
Normal
Membrane cofactor protein (MCP) or
CD46
including the non-portion downstream of
the gene containing the variant rs7144
Normal
C3 Normal
Complement factor I (CFI) Normal
Complement factor B (CFB) Normal
Thrombomodulin (THBD) Normal
ADAMTS13 Normal










The table shows the results of analyses by Next Generation Sequencing (NGS) of
complement genes and genes related to secondary complement disorders (13, 14).
The patient was homozygous for the aHUS risk allele CFRH1*B (9). For C5 the patient
was found wildtype (normal) for the two polymorphisms c.2672G>A (rs56040400) and
c.2671G>T (rs373359894), which are associated with a poor response to eculizumab
(15). #Loss of DGKE function results in a prothrombotic state, which may lead to
TMA/aHUS (16). *MMACHC is an inborn error of cobalamin metabolism. The consecutive
accumulation of homocysteine may trigger endothelial injury and TMA/aHUS (17).
syndrome. Seven years after the diagnosis of LPG, he presented
himself with end-stage renal disease. At this time, the diagnosis
of TMA was made. A detailed investigation of the complement
system found the homozygous aHUS risk allele CFHR1∗B, and a
functional complement assay demonstrated an overactivation of
the complement system.
LPG is an autosomal dominant disease with variable
penetrance caused by genetic alterations of the APOE gene (1).
In the presence of pathognomonic glomerular capillary lipid
thrombi, the diagnosis of LPG is straightforward. However,
expansive forces by accumulating lipoproteins can result in
mesangiolysis and glomerular basement membrane duplication
mimicking membranoproliferative glomerulonephritis (MPGN)
(6). LPG may also mimic TMA (18).
In our patient, we found a 9-bp deletion in exon 4
(c.480_488del), resulting in a 3-amino acid deletion, which was
previously associated with LPG (10, 11). According to a review
including the majority of patients with LPG (117 cases, all with
sequencing data of the APOE gene), the specific mutation found
in this case was previously discovered in China (5 cases) and
Japan (2 cases) (1). As the Chinese are the most significant ethnic
minority of foreign origin in Indonesia, it can be speculated that
our patient’s ancestors originate from China.
This case with LPG has several interesting aspects.
Dyslipidemia was no more present when the patient returned to
Switzerland, and he was off lipid-lowering therapy. This suggests
that the severe nephrotic syndrome at the initial presentation
contributed to the altered lipid profile. Our patient may belong
to a subgroup of individuals with LPG and dyslipidemia, which
manifests only under specific circumstances. Furthermore, over
the course of the disease, the patient developed TMA. In the
literature, we found only one TMA report in a patient with LPG,
attributed to malignant hypertension (19). Hypertension may
have contributed to TMA in our patient as well. However, the
reduced C3 levels suggest an overactivation of the alternative
complement pathway as an underlying mechanism. This is
further supported by the findings of an ex vivo assay with
the patient’s serum, which evoked increased binding of the
terminal complement complex C5b-9 to resting and activated
human endothelial cells (Table 3). Complementary, genetic
analyses of the complement system found homozygosity for
CFHR1∗B (Figure 2B), a finding strongly associated with aHUS
(9). A gene conversion event between the CFHR1 and CFH
genes resulted in CFHR1∗B, and functionally CFHR1∗B is
thought to compete with the complement regulatory factor
H on cell surfaces (9) (Figure 2C). Interestingly, patients
deficient in CFHR1 and CFHR3 have an increased risk for
aHUS also. Their susceptibility is associated with factor H
antibodies (9), which in turn may be due to modulation of B cell
activation (20).
We do not know what triggered aHUS in this patient
and to which extent aHUS accelerated renal function decline.
However, we obtained a laboratory result from Indonesia
showing thrombocytopenia 2 months before the patient returned
to Switzerland. This indicates that aHUS may have contributed
to the renal damage over a prolonged period.
Potentially, the APOE gene mutations associated with LPG
may facilitate aHUS in a patient at risk, as apoE structural
deformities caused by APOE mutations facilitate aggregation of
apoE. These aggregates may not only directly contribute to the
onset of LPG (4) but to the onset of aHUS also. As our patient’s
renal biopsy did not show any signs of TMA, the postulated apoE
aggregates alone seem to be insufficient to trigger aHUS in this
case. The lack of TMA signs in the renal biopsy (Figures 1A,B)
makes it also unlikely that TMA triggered the onset of
LPG. Additional factors such as hypertension and, further,
unknown risk factors must have contributed to this patient’s
disease course.
CONCLUSION
To the best of our knowledge, this is the first report of aHUS
in a patient with LPG with a documented dysfunction of the
complement system and an associated genetic risk factor.
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